Ricardo Rocha, MD

Leads the Global Medical Affairs organization responsible for advancing scientific exchange, generating impactful RWE and supporting the broad Madrigal’s pipeline in close collaboration with Commercial and Clinical Development across our key markets.

Leads overall Medical Affairs strategic vision, operations and long-range planning across the Intellia Tx platform. Member of Development Leadership Team. Responsible for creating a near term and long term global medical affairs organization, along with department policies and practices. Developing organizational structure to maintain company's resource optimization, prepare the Intellia organization for multiple simultaneous launches and adapt overall company to an evolving healthcare environment. Actively engaged in Development programs and other Intellia strategic initiatives, including building a Medical Affairs infrastructure fully integrated with Commercial and Clinical development to support execution of phase I-III clinical trials.

Leads overall Medical organization (~300 associates), including strategic vision, operations and long-range planning across the Region. Member of LaCan Pharma Executive Committee. Oversees Regional office Medical team as well as six Chief Scientific Officers. Partners with line function heads (Access, Commercial, Business innovation, etc.) on execution of company business strategy and engagement of external stakeholders in preparation for multiple simultaneous launches (Kesimpta, Inclisiran, Zolgensma, etc.) across diverse healthcare systems in the Region.

Leads cardiovascular CD&MA US program and builds cardio-renal and metabolism pipeline including 1 in-line (Entresto) and four development compounds (serelaxin, canakinumab, TQJ230 and LNP023). US medical lead in BD&L activities. Oversees team of >100 associates. Notable accomplishments: - Established industry-leading HF research and education program including successful completion of major clinical studies (PIONEER-HF - https://www.nejm.org/doi/full/10.1056/NEJMoa1812851), HF registry and best-in-industry multichannel education program. - Pioneered major implementation/dissemination research collaborations - Built leading culture in Novartis Pharma, reflected in internal cross divisional LWS surveys, medical execution metrics and external blinded surveys (ZS)

Leads overall US CD&MA strategic vision, operations and long-range planning across five therapeutic areas. Member of US Pharma Executive Committee. Directs six Vice Presidents/Medical Unit Heads, and four line function heads (HEOR/Medical Access, Clinical operations, Regulatory, Medical information/Field Medical) with oversight of ~500 associates. Continually enhances and redefines organizational structure to maintain company's resource optimization, prepare Medical organization for multiple simultaneous launches and helps adapts overall company to an evolving healthcare environment. Actively engages in Global Drug Development and Global Pharma strategic planning sessions. Notable Accomplishments: - Successfully drove 2020 medical planning/annual budget cycle, including strategic planning for four launches (Siponimod, Ofatumumab, Brolucizumab and Fevipiprant) through rigorous prioritization. - Recognized by US/Global leadership for outstanding culture and team contributions during a.i. role.

Leads HF clinical development and medical affairs program for Novartis HF portfolio in the US • Responsible for development and implementation of strategic plan for HF brands, including Entresto and Serelaxin • Partners with commercial team developing and implementing brand strategies and launch readiness plans for HF brands • Manages HF clinical trial program including 3 outcomes trials, >15 clinical trials and real world evidence studies • Partners with Global Development on preparation of regulatory strategy for serelaxin • People management: 10 direct reports

Leads development and implementation of US medical strategic vision and plan for LCZ696 • Design and execution of medical product plan • Develops highly differentiating, clinical/scientific platforms supporting medical communications for LCZ696 • Partners with key line functions to develop and present strategic vision, medical assessments, plans and recommendations to US Senior Leadership Teams at key Decision Points • Supports commercial team developing and implementing brand strategies and launch readiness plans for LCZ696, leading to strongly aligned medical and commercial plans • Leads internal/external medical communications around key milestones (PARADIGM HF outcomes trial results disclosure) and other major events • Leads medical team on design and execution of Phase IIIb/IV trials • Partners with Global Development on preparation of NDA for LCZ696 and execution of registrations trials in the US

• Major contributions developing and implementing global strategic vision and plans for multiple hypertension and heart failure brands (Diovan, Exforge, Rasilez, Serelaxin, LCZ696) • Design and execution of integrated strategic product plans as core member of Global Product Teams • Develops highly differentiating, clinical/scientific platforms supporting commercial positioning and market access strategy for new and in-line products resulting in industry leading launches (Exforge) • Partners with key line functions to develop and present strategic vision, medical/commercial assessments, plans and recommendations to Senior Leadership Teams at key Decision Points • Synergizes with commercial team developing and implementing brand strategies and launch readiness plans for new and in-line brands globally, leading to strongly aligned medical and commercial plans • Extensive experience in Japan, China and Emerging Growth Markets • Leads internal/external medical communications around key milestones (RELAX-AHF, NAVIGATOR, ALTITUDE, ASTRONAUT, ACCOMPLISH, VALUE outcomes trial results disclosure) and other major events (ALTITUDE early termination) • Robust crisis management experience including Senior Executive level updates and interactions • People management: 1-4 direct reports - direct responsibility for an extended team of 8-12 associates

• Planning and implementation of a global medical affairs programs for Serelaxin following completion of RELAX-AHF trial • Design and execution of integrated product strategic plan for serelaxin as core member of the Global Product Team • Managed medical communications for RELAX AHF, including internal and external communications around primary results presentation at AHA in Nov 2012 and training of Novartis Medical associates world-wide

- Global Development lead for Diovan/Exforge - Led team that successfully delivered one NDA submission in Switzerland (Diovan) and one type 2 variation submission in Europe (Exforge) - Successfully managed regulatory interactions with EMA to align on pediatric program for Diovan which ultimately led to a pediatric indication - Managed multifunctional development team with 5 direct reports and indirect responsibility for an extended team of 20+ associates

• Promoted from Associate Medical Director to Disease Area Head with increasing levels of responsibility for building the hypertension portfolio medical strategy for the USA • Successful execution of 20+ hypertension and heart failure clinical trials (including 5 mega-trials) from 2003-2010 • Built scientific platform supporting Diovan growth to blockbuster status and successful development and launch of Exforge, Exforge HCT and multiple aliskiren brands in the US • Established data-mining program for Diovan in 2004 that generated key new data with global impact • People management: 5-7 direct reports - direct responsibility for an extended team of 30+ associates

Head, Aliskiren Clinical Development and Medical Affairs Program in USA

Head, Clinical Development and Medical Affairs Program for Diovan, Exforge and Lotrel in USA

Head, Clinical Development and Medical Affairs Program for Exforge and Lotrel in USA

Lead for Medical Affairs program for Diovan in USA

Clinical Research Physician, Diovan

Built scientific platform to support launch readiness plans for hypertension - Post MI indications

• Led preclinical program for eplerenone - successful submission of hypertension NDA in the USA • Drove discovery research program for one additional drug candidate for heart failure